KRAS degradation averts PDAC chemoresistance

Laura Leonhardt; Matthias Hebrok

doi:10.1038/s43018-023-00708-7

KRAS degradation averts PDAC chemoresistance

Laura Leonhardt, Matthias Hebrok

Default

Publikation: Beitrag in Fachzeitschrift › Kommentar/Debatte

Abstract

Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.

Originalsprache	Englisch
Seiten (von - bis)	375-377
Seitenumfang	3
Fachzeitschrift	Nature Cancer
Jahrgang	5
Ausgabenummer	3
DOIs	https://doi.org/10.1038/s43018-023-00708-7
Publikationsstatus	Veröffentlicht - März 2024

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Zugriff auf Dokument

10.1038/s43018-023-00708-7

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{0e4a01a2ef754b71bc4617dbd5d2d87a,

title = "KRAS degradation averts PDAC chemoresistance",

abstract = "Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.",

author = "Laura Leonhardt and Matthias Hebrok",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc 2024.",

year = "2024",

month = mar,

doi = "10.1038/s43018-023-00708-7",

language = "English",

volume = "5",

pages = "375--377",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - KRAS degradation averts PDAC chemoresistance

AU - Leonhardt, Laura

AU - Hebrok, Matthias

N1 - Publisher Copyright: © Springer Nature America, Inc 2024.

PY - 2024/3

Y1 - 2024/3

N2 - Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.

AB - Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.

UR - http://www.scopus.com/inward/record.url?scp=85189169981&partnerID=8YFLogxK

U2 - 10.1038/s43018-023-00708-7

DO - 10.1038/s43018-023-00708-7

M3 - Comment/debate

C2 - 38538908

AN - SCOPUS:85189169981

SN - 2662-1347

VL - 5

SP - 375

EP - 377

JO - Nature Cancer

JF - Nature Cancer

IS - 3

ER -

KRAS degradation averts PDAC chemoresistance

Abstract

UN SDGs

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Dieses zitieren